Moreover, integrin αvβ6 is associated with poor clinical outcomes in multiple malignant tumors due to its roles in mediating the activation and release of TGFβ1.[12, 13, 14] The expression of integrin αvβ6 is tumor‐specific and highly upregulated in multiple tumors, including lung cancer, whereas the expression of αvβ6 in normal tissues and organs is typically low or undetectable.[15, 16, 17, 18] Therefore, the development of integrin αvβ6‐targeted diagnostic and therapeutic agents represents a promising direction for cancer research. This evidence concerns the gene TGFB1 and cancer.